appengine.ai

Artificial Intelligence | Machine Learning | Machine Perception Frontier Medicines | Discovering & Developing Medicines


Enterprise, Biotechnology, Pharmaceuticals, Healthcare, Patient Support San Francisco, California, United States

Frontier Medicines

Artificial Intelligence | Machine Learning | Machine Perception


Frontier Medicines | Discovering & Developing Medicines

Frontier Medicines

Biotechnology, Pharmaceuticals, Healthcare, Patient Support


San Francisco, California, United States

Frontier Medicines is a pre-clinical stage biopharmaceutical company developing breakthrough medicines that redefine the course of debilitating diseases. According to the American Cancer Society, 1,762,000 new cancer cases and 607,000 deaths from cancer are expected to occur in the US in 2019. Our focus is developing treatments against important cancer-causing proteins that the biopharma industry hasn’t found a way to treat (or “drug”) with pharmaceutical interventions. After decades of research, this has become one of the most critical challenges in addressing human disease and advancing oncology therapy --central to the research at Frontier Medicines. Frontier Medicines is using chemoproteomics – an innovative approach to chemically interrogate proteins in living systems – to discover and pharmacologically target new binding pockets (or “hotspots”) on proteins, making them accessible to small-molecule drug discovery and development. The company’s proprietary chemoproteomics platform also integrates advanced computational approaches and machine learning to further accelerate the path to drug discovery.

 

B2B

26 to 50

Series A

$67,000,000

Scaling Up

2018

 
 

Pharmaceuticals
Healthcare
Biotechnology

N/A

Increase Productivity

 
 

Analytics
Production
Service

Yes

Active

 
 

   Machine Learning
   Machine Perception


N/A


Image

Image

Video

Video

Text

Text

Time Series

Time Series

 

   Software


N/A


N/A

 
 

Dec 2020

  • Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets

Apr 2020

  • Graphcore Launches New Polar Analysis Tool

Feb 2020

  • Graphcore, the AI Chipmaker, Raises Another $150M at a $1.95B Valuation

Nov 2019

  • Microsoft and Graphcore Collaborate to Accelerate Artificial Intelligence

Sep 2019

  • FierceBiotech Names Frontier Medicines One of Its ?Fierce 15? Biotech Companies of 2019

Jul 2019

  • Frontier Medicines Announces Three Executive Hires: Chief Scientific Officer, Chief Technology Officer & Head of Degrader Technologies

Jun 2019

  • Frontier Medicines Launches with $67 Million to Develop Novel Medicines that Drug the ?Undruggable? Targets Driving Human Disease

Nov 2017

  • Graphcore and Sequoia Capital Partner for Growth
 
 

View All

Senior Scientist / Principal Scientist Biochemistry

San Francisco, California

Director / Associate Director, Chemical Biology

San Francisco, California

Senior Scientist, Medicinal Chemistry

San Francisco, California

Scientist / Senior Scientist, Computational Chemistry

San Francisco, California

Principal Scientist, Chemical Biology

San Francisco, California

 
 

9

1

$88.5 M

Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round

 
 

Date

Round

$ Raised

Investors

07/19/2021

Series B

$88.5 M

Woodline Partners LP, RA Capital Management, Deep Track Capital, ArrowMark Partners, Driehaus Capital Management, Sphera Healthcare, DCVC, DROIA, MPM Capital

Date : 07/19/2021

Round: Series B

$ Raised: $88.5 M

Investors: Woodline Partners LP, RA Capital Management, Deep Track Capital, ArrowMark Partners, Driehaus Capital Management, Sphera Healthcare, DCVC, DROIA, MPM Capital

 
 
Kevin Webster


Kevin Webster
CSO

Chris Varma


Chris Varma
Co-Founder, Chairman & CEO

Johannes Hermann, PhD


Johannes Hermann, PhD
CTO